Long-term follow-up of RTOG 88-05: Twice-daily external irradiation with brachytherapy for carcinoma of the cervix

International Journal of Radiation Oncology Biology Physics

Volumn 54, Issue 1, 2002, Pages 51-57

  Grigsby, Perry ^a   Winter, Kathryn ^b   Komaki, Ritsuko ^c   Marcial, Victor ^d   Eifel, Patricia ^c   Doncals, Desiree ^e   Stevens, Randy ^f   Rotman, Marvin ^g   Gaffney, David ^h  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b RADIATION THERAPY ONCOLOGY GROUP   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d Radiation Oncology Center   (United States)

^e SUMMA HEALTH SYSTEM   (United States)

^f White Plains Hospital Center   (United States)

^g SUNY DOWNSTATE MEDICAL CENTER   (United States)

^h UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

Author keywords

Brachytherapy; Cervix; Hyperfractionated irradiation; RTOG

Indexed keywords

FRACTIONATION; IRRADIATION; RADIOTHERAPY; TOXICITY;

SURVIVAL RATE;

ONCOLOGY;

ADOLESCENT; ADULT; ARTICLE; BRACHYTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; IMPLANT; MAJOR CLINICAL STUDY; METASTASIS; PARAAORTIC LYMPH NODE; PELVIS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE; RADIATION INJURY; SURVIVAL RATE; TREATMENT FAILURE; UTERINE CERVIX CARCINOMA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BRACHYTHERAPY; DOSE FRACTIONATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; RADIOTHERAPY DOSAGE; SURVIVAL RATE; UTERINE CERVICAL NEOPLASMS;

EID: 0036717878     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(02)02908-5     Document Type: Article

References (18)

1. Tumor size, irradiation dose, and long-term outcome of carcinoma of uterine cervix
2. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer
3. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer
4. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation, and adjuvant hysterectomy for bulky stage IB cervical carcinoma
5. Tolerance of pelvic normal tissues to hyperfractionated radiation therapy: Results of Protocol 83-08 of the Radiation Therapy Oncology Group
6. Twice-daily fractionation of external irradiation with brachytherapy in bulky carcinoma of the cervix: Phase I/II study of the Radiation Therapy Oncology Group 88-05
7. Prophylactic extended-field irradiation of para-aortic lymph nodes in stages IIB and bulky IB and IIA cervical carcinoma: Ten-year treatment results of RTOG 79-20
8. Irradiation with or without misonidazole for patients with stages IIIB and IVA carcinoma of the cervix: Final results of RTOG 80-05
9. Nonparametric estimation from incomplete observations
10. On the use of cause-specific and conditional failure probabilities
11. A class of K-sample tests for comparing the cumulative incidence of a competing risk
12. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinoma: First report of RTOG 9003
13. Twice-per-day fractionated high versus continuous low dose rate intracavitary therapy in the radical treatment of cervical cancer: A nonrandomized comparison of treatment results
14. Hyperfractionated external radiation therapy in stage IIIB carcinoma of uterine cervix: A prospective pilot study
15. A pilot study of concomitant boost accelerated superfractionated radiotherapy for stage III cancer of the uterine cervix
16. Accelerated hyperfractionated radiotherapy for locally advanced cervix cancer
17. Hyperfractionation in carcinoma of the cervix: Tumor control and late bowel complications
18. Modified partial hyperfractionation in radiotherapy for bulky uterine cervical cancer: Reduction of overall treatment time